Platelet refractoriness and alloimmunization

Area of Science:

• Transfusion Medicine
• Immunology
• Hematology

Background:

• Alloimmunization is a significant complication of blood transfusions.
• Leukocyte reduction and ultraviolet B (UVB) irradiation are key methods to modify blood products.
• Preventing alloantibody production is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of modified blood products in preventing alloimmunization.
• To compare leukocyte-reduced and UVB-irradiated blood components against standard products.
• To assess the impact of apheresis-derived platelets.

Main Methods:

• Prospective, randomized transfusion trials were conducted.
• Patients received either unmodified, leukocyte-reduced, or UVB-irradiated platelet concentrates.
• The Trial to Reduce Alloimmunization to Platelets (TRAP trial) involved 530 patients undergoing chemotherapy for acute myeloid leukemia.

Main Results:

• Leukocyte-reduced and UVB-irradiated blood components significantly decreased alloantibody production.
• Modified platelet components showed lower rates of alloimmune platelet refractoriness and lymphocytotoxic antibodies.
• No significant differences were observed among the three types of modified platelet components.

Conclusions:

• Leukocyte-reduced and UVB-irradiated platelet components are equally effective in preventing alloimmune-mediated platelet refractoriness.
• Apheresis-derived platelets offered no additional benefit over other modified components.
• Leukocyte reduction to <5 x 10(6) may be necessary to prevent alloantibody production.